Zepbound (tirzepatide) | Bluegrass Telehealth

Zepbound (tirzepatide):

Zepbound belongs to a class of medications called GLP-1/GIP receptor agonists.
It works by mimicking two naturally occurring hormones—GLP-1 and GIP—that help control appetite, slow digestion, and improve blood-sugar regulation.

This dual-action mechanism supports meaningful, long-term weight reduction and metabolic improvements.

Compound tirzepatide may be available for certain patients and conditions.

Compounded medications are prepared by licensed U.S. compounding pharmacies under prescription from a licensed clinician.

They are not FDA-approved products but are compounded in compliance with federal and state regulations to meet individual patient needs.

Our practice partners only with pharmacies that provide third-party sterility and potency testing for every batch.

Zepbound® is a registered trademark of Eli Lilly and Company.

Our telehealth practice is independently owned and not affiliated with Eli Lilly and Company.

Indications:

Chronic Weight Management (Obesity / Overweight)

Zepbound® (tirzepatide) is FDA-approved as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity (BMI ≥ 30 kg/m²) or overweight (BMI ≥ 27 kg/m²) with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol.

Zepbound helps regulate appetite and metabolism to promote clinically proven, sustainable weight loss when combined with lifestyle changes.

Obstructive Sleep Apnea (OSA)

Zepbound® (tirzepatide) is FDA-approved for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity.

By reducing body weight and improving upper-airway tone, Zepbound has been shown to significantly decrease the number of apnea and hypopnea events during sleep, leading to better rest, energy, and overall cardiometabolic health.